Home > Publications database > Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions > print

001     61776
005     20190404111822.0
024 7 _ |2 pmid
|a pmid:18413396
024 7 _ |2 DOI
|a 10.2967/jnumed.107.050005
024 7 _ |2 WOS
|a WOS:000255809100022
037 _ _ |a PreJuSER-61776
041 _ _ |a eng
082 _ _ |a 610
084 _ _ |2 WoS
|a Radiology, Nuclear Medicine & Medical Imaging
100 1 _ |a Floeth, F. W.
|b 0
|0 P:(DE-HGF)0
245 _ _ |a Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions
260 _ _ |a New York, NY
|b Society of Nuclear Medicine
|c 2008
264 _ 1 |3 online
|2 Crossref
|b Society of Nuclear Medicine
|c 2008-04-15
300 _ _ |a 730 - 737
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |a Journal of Nuclear Medicine
|x 0097-9058
|0 3621
|v 49
500 _ _ |a Record converted from VDB: 12.11.2012
520 _ _ |a Nonspecific incidental brain lesions (NILs) are being detected more frequently because of an increasing number of screening or research MRI scans of the brain, and their natural course is uncertain.In a prospective cohort study starting in 1999, we determined the outcomes of patients with incidental, nonenhancing, supratentorial, lobar, and small-volume (<10 mL) lesions, depending on the findings of MRI and PET with the (18)F-labeled amino acid fluoroethyl-l-tyrosine ((18)F-FET). Patients with seizures, focal neurologic deficits, signs of local or systemic infection or inflammation, known brain disease, or any kind of previous cerebral treatment were excluded. Finally, 21 patients were eligible. MRI was performed in 19 of these patients because of nonspecific symptoms (such as headaches, dizziness, or sudden deafness), whereas 2 patients were healthy volunteers in MRI studies. Clinical follow-up and MRI scans were obtained at 4- to 6-mo intervals, and follow-up ranged from 3 to 8.5 y. Mean lesion-to-brain (L/B) ratios of >or=1.6 on (18)F-FET PET were rated as positive.Four different outcome groups were identified. In group A, 5 NILs regressed or vanished completely. All of these lesions were circumscribed on MRI, and (18)F-FET uptake was negative, with an L/B ratio of 1.2+/-0.2 (mean +/- SD). In group B, 10 NILs were stable, without growth. All of these lesions were circumscribed on MRI, and (18)F-FET uptake was negative (L/B ratio: 1.0+/-0.1). In group C, 2 NILs grew slowly over years, and an astrocytoma of World Health Organization (WHO) grade II was diagnosed after resection in each case. The lesions were circumscribed on MRI, and (18)F-FET uptake was negative (L/B ratios: 0.7 and 1.0). In group D, 4 NILs showed sudden and rapid growth, with clinical deterioration, and a high-grade glioma of WHO grade III or IV was diagnosed after resection in all cases. The lesions were diffuse on MRI, and (18)F-FET uptake was significantly increased (L/B ratio: 2.0+/-0.4) (P<0.01 for group D vs. group A or group B).For NILs, a circumscribed growth pattern on MRI and normal or low (18)F-FET uptake on PET are strong predictors for a benign course, with the eventual development of a low-grade glioma. In contrast, NILs with a diffuse growth pattern on MRI and increased (18)F-FET uptake indicate a high risk for the development of a high-grade glioma.
536 _ _ |a Funktion und Dysfunktion des Nervensystems
|c P33
|2 G:(DE-HGF)
|0 G:(DE-Juel1)FUEK409
|x 0
588 _ _ |a Dataset connected to Web of Science, Pubmed
650 _ 2 |2 MeSH
|a Adolescent
650 _ 2 |2 MeSH
|a Adult
650 _ 2 |2 MeSH
|a Aged
650 _ 2 |2 MeSH
|a Brain: pathology
650 _ 2 |2 MeSH
|a Child
650 _ 2 |2 MeSH
|a Disease Progression
650 _ 2 |2 MeSH
|a Female
650 _ 2 |2 MeSH
|a Glioma: metabolism
650 _ 2 |2 MeSH
|a Glioma: pathology
650 _ 2 |2 MeSH
|a Glioma: radionuclide imaging
650 _ 2 |2 MeSH
|a Humans
650 _ 2 |2 MeSH
|a Magnetic Resonance Imaging
650 _ 2 |2 MeSH
|a Male
650 _ 2 |2 MeSH
|a Middle Aged
650 _ 2 |2 MeSH
|a Positron-Emission Tomography: methods
650 _ 2 |2 MeSH
|a Prognosis
650 _ 2 |2 MeSH
|a Tyrosine: analogs & derivatives
650 _ 2 |2 MeSH
|a Tyrosine: diagnostic use
650 _ 7 |0 0
|2 NLM Chemicals
|a O-(2-fluoroethyl)tyrosine
650 _ 7 |0 55520-40-6
|2 NLM Chemicals
|a Tyrosine
650 _ 7 |a J
|2 WoSType
653 2 0 |2 Author
|a incidental finding
653 2 0 |2 Author
|a nonspecific brain lesions
653 2 0 |2 Author
|a F-18-fluoroethyl-L-tyrosine
653 2 0 |2 Author
|a PET
653 2 0 |2 Author
|a MRI
653 2 0 |2 Author
|a prognosis
700 1 _ |a Sabel, M.
|b 1
|0 P:(DE-HGF)0
700 1 _ |a Stoffels, G.
|b 2
|u FZJ
|0 P:(DE-Juel1)131627
700 1 _ |a Pauleit, D.
|b 3
|0 P:(DE-HGF)0
700 1 _ |a Hamacher, K.
|b 4
|u FZJ
|0 P:(DE-Juel1)VDB551
700 1 _ |a Steiger, H. J.
|b 5
|0 P:(DE-HGF)0
700 1 _ |a Langen, K. J.
|b 6
|u FZJ
|0 P:(DE-Juel1)131777
773 1 8 |a 10.2967/jnumed.107.050005
|b : Society of Nuclear Medicine, 2008-04-15
|n 5
|p 730-737
|3 journal-article
|2 Crossref
|t Journal of Nuclear Medicine
|v 49
|y 2008
|x 0161-5505
773 _ _ |a 10.2967/jnumed.107.050005
|g Vol. 49, p. 730 - 737
|p 730-737
|n 5
|q 49<730 - 737
|0 PERI:(DE-600)2040222-3
|t Journal of nuclear medicine
|v 49
|y 2008
|x 0161-5505
856 7 _ |u http://dx.doi.org/10.2967/jnumed.107.050005
909 C O |o oai:juser.fz-juelich.de:61776
|p VDB
913 1 _ |k P33
|v Funktion und Dysfunktion des Nervensystems
|l Funktion und Dysfunktion des Nervensystems
|b Gesundheit
|0 G:(DE-Juel1)FUEK409
|x 0
914 1 _ |y 2008
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |k INB-3
|l Medizin
|d 31.12.2008
|g INB
|0 I:(DE-Juel1)INB-3-20090406
|x 0
920 1 _ |k INB-4
|l Nuklearchemie
|d 31.12.2008
|g INB
|0 I:(DE-Juel1)VDB807
|x 1
970 _ _ |a VDB:(DE-Juel1)97283
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)INB-3-20090406
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)INM-5-20090406

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21